Biotech News

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

MaxCyte (MXCT)MaxCyteCompany update

Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially approved therapies Akron Bio is expected to generate approximately $28 million

Related news

MXCTMaxCyte2026-11-10 11:01 EST

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MXCTMaxCyte2026-10-14 12:05 EST

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

TSHATaysha Gene Therapies2026-08-03 12:00 EST

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

OCGNOcugen2026-10-14 10:30 EST

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

RHHBYRoche Holdings AG2026-11-10 06:00 EST

Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

RHHBYRoche Holdings AG2026-10-19 05:00 EST

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

GSKGSK plc2026-10-16 13:49 EST

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

RCKTRocket Pharmaceuticals2026-11-12 21:00 EST

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

Stock data

Close
1.28 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States